Enzo Biochem Inc. (NYSE:ENZ) announced today that Robert Boorstein, MD,
PhD, an Associate Professor of Pathology at the NYU School of Medicine,
has been appointed Medical Director of Enzo Clinical Labs, a full
service clinical reference laboratory serving the metropolitan New York
City medical community.
"The appointment of Dr. Boorstein, a highly regarded pathologist who
until recently was Director of Pathology at the world renowned Bellevue
Hospital Center, to our staff is a major addition to our Lab, and is in
keeping with the ongoing transformative program we have underway to
broaden and diversify its scope, ” said Dr. Kevin Krenitsky, President
of Enzo Clinical Labs.
"Dr. Boorstein brings with him over 25 years of particularly rich
experience as a pathologist and medical laboratory director that will
enable us to continue our program to forge ahead in providing the latest
state-of-the-art diagnostic testing procedures,” added Dr. Krenitsky.
Dr. Boorstein received his M.D. from Harvard Medical School, along with
a M.A. and PhD in Pharmacology from Harvard University, and a B.A. summa
cum laude, from the same University. Following his residency in
pathology at the NYU School of Medicine, he remained on the faculty and
subsequently became Director of Pathology at Bellevue Hospital/NYU
Shared Laboratories. In this position, he directed the consolidation of
laboratories within the South Manhattan and North Manhattan Healthcare
Networks of the NYC Health and Hospital Corporation, and oversaw the
expansion and modernization of the Bellevue Hospital laboratory. He has
also been associated with Tisch Hospital and served as Director of
Pathology at Lincoln Hospital, in addition to spending a year as a
Visiting Scholar at Laboratoire de Chimie, C.E.N.G., Grenoble, a
research institution in France. He has been associated with numerous
professional groups and committees, and has written extensively for
professional journals. He is widely recognized for his expertise in
technology assessment and the linkage of diagnostics and therapeutics.
About Enzo
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and
biotechnology company focused on harnessing biological process to
develop research tools, diagnostics and therapeutics, and serves as a
provider of test services, including exotic tests, to the medical
community. Since our founding in 1976, our strategic focus has been on
the development of enabling technologies in the life sciences field.
Enzo Life Sciences develops, produces and markets proprietary labeling
and detection products for gene sequencing, genetic analysis and
immunological research, among others. Its catalog of over 40,000
products serve the molecular biology, drug discovery and pathology
research markets worldwide. Enzo Clinical Labs division provides
laboratory services for a growing roster of physicians in the New York
Metropolitan area, as well as parts of New Jersey and Pennsylvania. Its
tests include, in addition to routine tests, capabilities for detecting
molecular infection disease, molecular oncology, autoimmune disorders
and genetics. Enzo Clinical Labs also provides clinical diagnostic
services that allow Enzo to capitalize on its extensive advanced
molecular and cytogenetic capabilities and the broader trends in
predictive and personalized diagnostics. Enzo Therapeutics is a
biopharmaceutical venture that has developed multiple novel approaches
in the areas of gastrointestinal, infectious, ophthalmic and metabolic
diseases. It has focused its efforts on developing treatment regimens
for diseases and conditions for which current treatment options are
ineffective, costly, and/or cause unwanted side effects. In the course
of the company’s research and development activities, Enzo has developed
a substantial portfolio of intellectual property assets, with 249 issued
patents worldwide and over 200 pending patent applications.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
